ASCO 2019 Frontline Pembrolizumab Is promising alternative to chemotherapy for advanced gastroesophageal junction and gastric cancers

ASCO 2019: Front-line Pembrolizumab Is promising alternative to chemotherapy for advanced gastroesophageal junction and gastric cancers

10:06 EDT 1 Jun 2019 | ecancermedicalscience

The KEYNOTE-062 phase III randomised clinical trial achieved its primary endpoint, showing that for patients with PD-L1-positive, HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) cancer, initial therapy with pembrolizumab resulted in...

More From BioPortfolio on "ASCO 2019: Front-line Pembrolizumab Is promising alternative to chemotherapy for advanced gastroesophageal junction and gastric cancers"